{"id":"NCT02629393","sponsor":"Origin Biosciences","briefTitle":"Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A","officialTitle":"A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-05","primaryCompletion":"2022-09","completion":"2022-10","firstPosted":"2015-12-14","resultsPosted":"2023-10-17","lastUpdate":"2023-10-17"},"enrollment":5,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Molybdenum Cofactor Deficiency, Type A"],"interventions":[{"type":"DRUG","name":"ORGN001 (formerly ALXN1101)","otherNames":[]}],"arms":[{"label":"ORGN001 (formerly ALXN1101)","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and efficacy of ORGN001(formerly ALXN1101) in neonate patients with MoCD Type A","primaryOutcome":{"measure":"Overall Survival","timeFrame":"Through last observation (average of 24 months)","effectByArm":[{"arm":"ORGN001 (Formerly ALXN1101)","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Day","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["United States","Israel","Norway","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214018Orig1s000TOC.cfm"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":5},"commonTop":["Hypoglycaemia","Hypocalcaemia","Catheter site infection","Vomiting","Pneumonia"]}}